Website News and Research

RSS

Seasonal flu shots: Are they responsible for the adverse reactions? Investigations on

After the seasonal flu vaccines caused over 250 cases of fever, vomiting and convulsions and one reported death in under-fives there has been intense investigations to detect the cause. Further vaccinations were stopped last Friday.

28 Apr 2010

The Prevention Plan program for Nevada PEBP employees and retirees

State of Nevada public employees are taking steps to get healthier and feel better by participating in The Prevention Plan, a U.S. Preventive Medicine program designed to encourage healthy behaviors, detect disease in the earliest stages and manage chronic conditions before they progress.

28 Apr 2010

China lifts ban on tourists suffering from HIV/AIDS

In a new development China has lifted its decades old reservations towards travelers and tourists suffering from HIV and AIDS in the wake of the Shanghai World Expo this weekend.

28 Apr 2010

Nile Therapeutics closes underwritten public offering of common stock

Nile Therapeutics, Inc., a company focused on the development of novel therapeutics for heart failure patients, announced the closing of its previously announced underwritten public offering of 6,500,000 units of its securities consisting of an aggregate of 6,500,000 shares of common stock and warrants to purchase an aggregate of 1,950,000 shares of common stock.

28 Apr 2010

Biostar receives Shaanxi SFDA approval to market Xin Aoxing Oleanolic Acid Capsules

Biostar Pharmaceuticals, Inc., the Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsule, and other pharmaceutical products, announced today it has received new advertising approval from Shaanxi State Food and Drug Administration for marketing Xin Aoxing Oleanolic Acid Capsules.

27 Apr 2010

European commission's FP7 programme allocated euro 6.10 billion

Europe is moving towards becoming a knowledge-based economy. Keeping in line with this objective, the European commission has instituted the Framework 7 (FP7) programme. Launched to support the re-launched Lisbon strategy, FP7 focuses on research themes rather than the framework programmes of the past. It has been designed to meet some of the persisting challenges of raising Europe to match global excellence in research, thereby benefiting the European life science funding.

27 Apr 2010

AHRQ releases Health Literacy Universal Precautions Toolkit

Several studies have found that a majority of American adults have trouble with basic health literacy tasks such as reading and understanding prescription drug labels and following their doctors' instructions correctly.

26 Apr 2010

General Dynamics Information Technology awarded task order to support HHS' CMS

General Dynamics Information Technology's VIPS business sector, a business unit of General Dynamics, has been awarded a task order to support the Department of Health and Human Services' Centers for Medicare and Medicaid Services.

26 Apr 2010

National Securities, MD Becker Partners to host SCIENCE program

National Securities Corporation and MD Becker Partners will host their inaugural Stem Cell Investor & Executive Networking Conference Event on June 1, 2010, from 11:00am to 3:00pm (EDT), at National Securities Corporation Global Headquarters at 120 Broadway, (2nd Floor Conference Center) in New York City.

26 Apr 2010

New website to counter misguided 'mercury facts'

At the "International Mercury Expo 2010*" this weekend at the College of William and Mary, a mercury watchdog group is launching a new website to counter misinformation on 'mercury facts' spread by industry and groups claiming to represent consumers – but in reality often representing special interests in disguise.

24 Apr 2010

Physician panel to discuss issues related to Qutenza at Investor Day

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and CEO, and members of the NeurogesX management team, will host an Investor Day on Friday, April 30, 2010, from 8:15am-11:00am EDT in New York City

24 Apr 2010

WuXi PharmaTech announces filing of 2009 annual report on Form 20-F

WuXi PharmaTech (Cayman) Inc. today announced that it filed its annual report on Form 20-F for the year ended December 31, 2009 with the Securities and Exchange Commission.

24 Apr 2010

LFA felicitates Yale University professor on receipt of US DoD's PRMRP research grant

The Lupus Foundation of America, Inc. (LFA) congratulates Insoo Kang, M.D., Associate Professor of Medicine, Yale University for being selected to receive a $1.2 million research grant from the U.S. Department of Defense's (DoD) Congressionally Directed Peer Reviewed Medical Research Program (PRMRP). The DoD award will fund a three-year study that will investigate whether and why lupus patients make more of the chemical interleukin (IL-27), which causes decreased generation of T cells and is known to play an important role in autoimmunity and lupus.

24 Apr 2010

EpiCept invites stockholders to attend Annual Meeting

With this notice, stockholders of EpiCept Corporation are invited to the Annual Meeting of Stockholders on June 3, 2010, at 10:00 a.m. Eastern time at the Dolce/IBM Palisades Executive Conference Center, 334 Route 9W, Palisades, New York 10964.

23 Apr 2010

Geron scientists highlight importance of telomerase inhibitor, GRN163L at AACR 2010

Geron Corporation today announced five presentations by Geron scientists and collaborators on the company's telomerase inhibitor, imetelstat sodium, including the drug's activity against cancer stem cells, at the 101st American Association for Cancer Research annual meeting held in Washington D.C.

23 Apr 2010

Essilorl's first-quarter 2010 consolidated revenues up 7.8%

Essilor International, the world leader in ophthalmic optics, today announced that consolidated revenue for the three months ended March 31, 2010 rose by 7.8% to EUR905.8 million, in line with stated objectives.

23 Apr 2010

Transposagen Biopharmaceuticals announces new TGEM Rat Model product line

Transposagen Biopharmaceuticals, Inc., based in Lexington, KY, has announced today that it has added 170 genetically modified rats and related biomaterials to its database of laboratory rats with a genetic modification that can mimic a human disease. These animals are used by academic, pharmaceutical, and biotech scientists for drug discovery and development research and will be sold under Transposagen's new TGEM(TM) Rat Models brand.

23 Apr 2010

Nile Therapeutics prices underwritten public offering of common stock

Nile Therapeutics, Inc., a company focused on the development of novel therapeutics for heart failure patients, announced the pricing of its previously announced underwritten public offering of 6,500,000 units of its securities at a public offering price of $0.70 per unit. Each unit consists of one share of Nile common stock and 0.30 warrants to purchase common stock.

23 Apr 2010

COSMOS project launched to investigate link between use of mobile phones and health problems

A new decades-long study launches today to investigate whether there is a link between the use of mobile phones and long-term health problems such as cancer.

23 Apr 2010

Researchers use electronic medical records for injury management and surveillance during marathon

Henry Ford Hospital researchers have brought the use of electronic medical records out of the hospital setting and into the streets by using the technology for a marathon.

23 Apr 2010